Analysis of opposing histone modifications H3K4me3 and H3K27me3 reveals candidate diagnostic biomarkers for TNBC and gene set prediction combination
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Breast cancer encompasses a major portion of human cancers and must be carefully monitored for appropriate diagnoses and treatments. Among the many types of breast cancers, triple negative breast cancer (TNBC) has the worst prognosis and the least cases reported. To gain a better understanding and a more decisive precursor for TNBC, two major histone modifications, an activating modification H3K4me3 and a repressive modification H3K27me3, were analyzed using data from normal breast cell lines against TNBC cell lines. The combination of these two histone markers on the gene promoter regions showed a great correlation with gene expression. A list of signature genes was defined as active (highly enriched H3K4me3), including NOVA1, NAT8L, and MMP16, and repressive genes (highly enriched H3K27me3), IRX2 and ADRB2, according to the distribution of these histone modifications on the promoter regions. To further enhance the investigation, potential candidates were also compared with other types of breast cancer to identify signs specific to TNBC. RNA-seq data was implemented to confirm and verify gene regulation governed by the histone modifications. Combinations of the biomarkers based on H3K4me3 and H3K27me3 showed the diagnostic value AUC 93.28% with P-value of 1.16e-226. The results of this study suggest that histone modification analysis of opposing histone modifications may be valuable toward developing biomarkers and targets for TNBC.
Abstract
Breast cancer encompasses a major portion of human cancers and must be carefully monitored for appropriate diagnoses and treatments. Among the many types of breast cancers, triple negative breast cancer (TNBC) has the worst prognosis and the least cases reported. To gain a better understanding and a more decisive precursor for TNBC, two major histone modifications, an activating modification H3K4me3 and a repressive modification H3K27me3, were analyzed using data from normal breast cell lines against TNBC cell lines. The combination of these two histone markers on the gene promoter regions showed a great correlation with gene expression. A list of signature genes was defined as active (highly enriched H3K4me3), including NOVA1, NAT8L, and MMP16, and repressive genes (highly enriched H3K27me3), IRX2 and ADRB2, according to the distribution of these histone modifications on the promoter regions. To further enhance the investigation, potential candidates were also compared with other types of breast cancer to identify signs specific to TNBC. RNA-seq data was implemented to confirm and verify gene regulation governed by the histone modifications. Combinations of the biomarkers based on H3K4me3 and H3K27me3 showed the diagnostic value AUC 93.28% with P-value of 1.16e-226. The results of this study suggest that histone modification analysis of opposing histone modifications may be valuable toward developing biomarkers and targets for TNBC.
참고문헌 (18)
- Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
- O'Brien KM, "Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study", Clin Cancer Res, 16, pp.6100~6110 (2010)
- Perou CM, "Molecular stratification of triple-negative breast cancers", Oncologist, 16(Suppl 1), pp.61~70 (2011)
- Carey LA, "Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study", JAMA, 295, pp.2492~2502 (2006)
- Jones PA, "The epigenomics of cancer", Cell, 128, pp.683~692 (2007)
- Chen X, "A novel subtype classification and risk of breast cancer by histone modification profiling", Breast Cancer Research and Treatment, 157, pp.267~279 (2016)
- Koch CM, "The landscape of histone modifications across 1% of the human genome in five human cell lines", Genome Res, 17, pp.691~707 (2007)
- Barski A, "High-resolution profiling of histone methylations in the human genome", Cell, 129, pp.823~837 (2007)
- Xi Y, "Histone modification profiling in breast cancer cell lines highlights commonalities and differences among subtypes", BMC Genomics, 19, pp.150~ (2018)
- Gomez-Cabrero D, "Data integration in the era of omics : current and future challenges", BMC Syst Biol 8 Suppl, 2, pp.I1~ (2014)
- Chaligne R, "The inactive X chromosome is epigenetically unstable and transcriptionally labile in breast cancer", Genome Res, 25, pp.488~503 (2015)
- Tang Z, "GEPIA : a web server for cancer and normal gene expression profiling and interactive analyses", Nucleic Acids Res, 45, pp.W98~W102 (2017)
- Nebbioso A, "Cancer epigenetics : Moving forward", PLoS Genet, 14, pp.e1007362~ (2018)
- Zand B, "Role of Increased n-acetylaspartate Levels in Cancer", J Natl Cancer Inst, 108, pp.djv426~ (2016)
- Sun C, "SOX5promotes breast cancer proliferation and invasion by transactivation of EZH2", Oncol Lett, 17, pp.2754~2762 (2019)
- Wolf J, "An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation", Oncogene, 33, pp.4273~4278 (2014)
- Ma C, "SALL1 functions as a tumor suppressor in breast cancer by regulating cancer cell senescence and metastasis through the NuRD complex", Mol Cancer, 17, pp.78~ (2018)
- Rahman M, "Alternative preprocessing of RNASequencing data in The Cancer Genome Atlas leads to improved analysis results", Bioinformatics, 31, pp.3666~3672 (2015)